Literature DB >> 8941041

The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps.

R H Mattson1.   

Abstract

Epilepsy is common in individuals who are mentally retarded and/or otherwise multiply handicapped. These patients often display several seizure types. Seizure control may be difficult and drug interactions common because of polytherapy. Cognitive, behavioral, affective, and motor problems in these patients often confound accurate diagnosis and effective management. Treatment often requires not only antiepileptic drugs (AEDs) but also psychoactive drugs and/or environmental and personal support. To minimize unwanted drug effects, therapeutic strategies should focus on the administration of the fewest possible drugs at the lowest effective dose. The new AEDs may be of special value at times in these populations because they offer potential for improved efficacy, but especially because many of them provide better safety profiles and fewer pharmacokinetic interactions with other drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8941041     DOI: 10.1111/j.1528-1157.1996.tb06039.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  3 in total

Review 1.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

2.  Vagal Nerve Stimulation in Epilepsy: Experiences of Participants with Cognitive Deficits.

Authors:  Eva Pipan; Alexandros Apostolou; Maria Bograkou; Petra Brooks; Patrick Vigren; Helena Gauffin
Journal:  Neuropsychiatr Dis Treat       Date:  2020-05-08       Impact factor: 2.570

3.  Individual vulnerabilities to psychosis after antiepileptic drug administration.

Authors:  Nozomi Akanuma; Naoto Adachi; Peter Fenwick; Masumi Ito; Mitsutoshi Okazaki; Koichiro Hara; Ryouhei Ishii; Masanori Sekimoto; Masaaki Kato; Teiichi Onuma
Journal:  BMJ Neurol Open       Date:  2020-08-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.